Floatz logo

Flibanserin

Hyposexual Desire Disorder

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hyposexual Desire Disorder cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
BioSante Pharmaceuticals
Phase 3B

Same molecule, other indications

Flibanserin is also rated in:

prostate adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →